
|Videos|May 3, 2022
Pharmaceutical CEO Leadership: Real-World Evidence
Among the topics discussed at Pharm Exec’s recent RWE roundtable are how the pandemic has served to validate the use of RWE/RWD; the most important features of a real-world data set; and key considerations when selecting an RWD partner.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
2
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5




